Insights

Alpha | Laurus Labs Ltd. – Equity Research Desk

March 30, 2026 . Equities Desk

Alpha . Equity Research

Laurus Labs Ltd. – Chemistry for Better Living

Laurus Labs Limited, incorporated in 2005 and headquartered in Hyderabad, India, is a research-driven, integrated pharmaceutical company with a diversified presence across Active Pharmaceutical Ingredients (APIs), Finished Dosage Forms (FDF), Contract Development and Manufacturing (CDMO), and Biotechnology segments, catering to global markets across therapeutics such as antiretrovirals (ARVs), oncology, and other complex segments. The company operates 15 development and manufacturing facilities, has over 7,800 KL reactor capacity, and maintains partnerships with 6 global pharma companies, supported by a strong R&D engine with 237 patents granted.

Products and Services

The company operates across four core business segments: Contract Development and Manufacturing (CDMO), Generics – Finished Dosage Forms (FDF) & Active Pharmaceutical Ingredients (API), and Biotechnology.

CDMO – Provides end-to-end drug development and manufacturing services to global pharmaceutical, biotechnology, crop science, animal health, and specialty ingredient companies, with key markets including the US, EU, and Japan.
Generics (API and FDF) – The company is among the leading third-party suppliers of antiretroviral (ARV) APIs globally, supported by one of the largest high-potent API capabilities in India. Its portfolio spans ARV, oncology, steroids, hormones, and cardiovascular therapies, catering to major global generic pharmaceutical companies. The FDF segment focuses on oral solid dosage formulations.
Biotechnology – Offers integrated services ranging from clone and strain engineering to large-scale production, supporting clients across the microbial precision fermentation value chain. Its solutions cater to areas such as regenerative medicine, vaccines, and cultured meat.

Subsidiaries: As of FY25, the company has 8 subsidiaries, 2 associate companies and a joint venture.

Investment Rationale

Volume driven generics growth with stable pricing dynamics – Laurus holds one of the strongest positions globally as a supplier of ARV APIs, and this is generating stable earnings from the division. The generics business delivered Rs.1,327 crore in Q3FY26 (+37% YoY), driven primarily by volume. ARV annual guidance has been revised upward from Rs.2,500 crore to Rs.2,600 crore (±Rs.200 crore), supported by completed debottlenecking of ARV manufacturing lines and reallocation of capacity, which was disclosed as complete in Q2FY26. Beyond ARV, strong offtake from recently launched products in developed markets (US, Canada, EU) is adding a new non-ARV FDF revenue layer. The oral solid facility expansion is progressing well, a significant part of the new plant capacity became operational in Q3FY26, and the 3 billion tablet capacity in Unit II for the KRKA CMO partner came online with revenue expected from Q1FY27. The KRKA Pharma joint venture is constructing an FDF manufacturing facility in Hyderabad with Phase-1 completion expected by mid-2027, providing a durable European formulation revenue channel. CMO activity levels are rising with good utilisation visibility.

Scaling a future ready CDMO platform – The CDMO business grew 43% in 9MFY26, supported by strong recurring business from existing long-term customer relationships. Three commercial NCEs (New Chemical Entity) were supplied in the last 18 months. Over 110 active pipeline projects are in execution, with a well-balanced mix of big pharma and mid-sized biotechs. Management is expecting the CDMO business to grow Q4FY26. On capability-building: Laurus has made significant investments in peptide development and manufacturing infrastructure, with qualification of commercial-scale peptide facilities expected within CY26. Large-scale capacity expansion continues at Vizag, expanding capabilities including peptides, flow chemistry, high-energy chemistries and purifications. The antibody drug conjugate and gene therapy process development lab has been operationalised in Hyderabad, and construction of the GMP manufacturing facility is on track – though meaningful ADC revenues are not expected in the next two years, this positions Laurus ahead of the curve in next-generation CDMO modalities. In the Bio division, while Q3 was muted, construction of the commercial-scale fermentation facility at Vizag is progressing as planned, with Phase-1 capacity of over 400 kiloliters expected to be operational by end of 2026, unlocking the next leg of Bio CDMO growth. Management expects CDMO’s contribution to total revenues to grow over time (currently 30%).

Margins expanding, balance sheet strengthening – EBITDA margins have expanded every single quarter for three consecutive quarters – 24.8% → 26.0% → 27.3%, driven by better product mix and operating efficiency, with management guiding a 60% gross margin floor for Q4FY26 and FY27. ROCE has improved progressively from 12.7% to 16.3% to 18.5% over the last three quarters, with further improvement guided. Simultaneously, the balance sheet has been rapidly deleveraged and operating cash flow of Rs.1,477 Cr in 9MFY26 comfortably self-funds the Rs.735 crore CAPEX deployed in the same period.

Q3FY26 – In Q3, the company reported a revenue of Rs.1,778 crore, up 26% YoY. EBITDA grew 70% YoY, to Rs.485 crore, driven by a wide expansion in EBITDA margins of 720bps to 27%. PAT increased 174% Rs.252 crore (14.2% margin, up from 6.5% in Q3FY25).

FY25 – In FY25, revenue grew 10% YoY to Rs.5,554 crore. EBITDA was recorded at Rs.1,115 crore (20% Margin), up 40% YoY, and PAT grew 112% YoY to Rs.358 crore.
Financial Performance – The 3-year revenue and net profit CAGR stand at 4%, and -27%, however, the TTM revenue and net profit growth have drastically improved to 27% and 321%, respectively. The 3-year average ROE and ROCE are around 11% and 13%, and the company carries a debt-to-equity ratio of 0.46, serviced by an interest coverage ratio of ~7x.

Industry

The Indian pharmaceutical industry is a global leader in generic medicines and low-cost vaccines, ranking as the world’s 3rd largest market by volume and 14th by value. According to Bain & Co., the Indian pharmaceutical market was valued at Rs. 4,71,295 crore (US$ 55 billion) in 2025 and is projected to reach Rs. 10,28,280–11,13,970 crore (US$ 120–130 billion) by 2030. India contributes 20% of global generic exports by volume and supplies 55-60% of UNICEF’s vaccines and 99% of WHO DPT vaccine demand, underscoring its manufacturing depth and cost advantages.

Growth Drivers

FDI & Policy Support – 100% FDI is permitted under the automatic route for greenfield pharmaceutical projects, with 74% permitted for brownfield investments.
Rising Healthcare Demand & Chronic Disease Burden – India’s growing middle class, expanding healthcare access, and increasing prevalence of chronic illnesses such as diabetes, cardiovascular disorders, and CNS conditions continue to drive long-term demand.
Expansion of Domestic Manufacturing & API Self-Reliance – Government schemes such as the Production-Linked Incentive (PLI) for pharmaceuticals, bulk drug parks, and support for KSM/API manufacturing are reducing import dependence and enabling large-scale domestic capacity creation.

Peer Analysis

Competitors – Zydus Lifesciences Ltd, Cipla Ltd, etc.

Compared to peers such as Cipla and Zydus Lifesciences, Laurus Labs has a relatively higher exposure to APIs and CDMO, positioning it more upstream in the pharmaceutical value chain, alongside its formulations business. In contrast, peers have a larger presence in branded formulations, particularly in domestic markets.

The company’s relatively lower return ratios are consistent with its ongoing investment phase, marked by capacity expansion and investments in new capabilities, which typically involve longer gestation periods before full utilization and operating leverage benefits are realized.

Outlook

Management has guided gross margins of approximately 60% for Q4FY26 and through FY27, supported by a favourable product and division mix, with EBITDA margins expected to improve further as operating leverage builds. ROCE, which has improved progressively to 18.5% over the last three quarters, is guided to move higher as asset utilisation increases toward the normalised 1.1x target. The most critical near-term signal to watch is Q4FY26 CDMO performance, management has explicitly committed to CDMO growing year-on-year over Q4FY25 (Rs.461 Cr), and delivery on this will confirm that the business is transitioning from lumpy development-led campaigns to recurring commercial supplies, which management has guided will constitute the majority of FY27 CDMO revenues. On ARVs, the annual run rate has been revised upward to Rs.2,600 ± 200 Cr following completed capacity debottlenecking, with growth remaining volume-led and stable though continued monitoring of PEPFAR and Global Fund procurement decisions remains essential given ARV’s ~40% contribution to total revenues.

Valuations

We believe Laurus Labs is entering a phase of earnings re-rating, supported by stable generics cash flows and a CDMO segment scaling from development-led revenues to commercial supplies. We recommend a BUY rating in the stock with the target price (TP) of Rs.1,188, 60x FY27E EPS. We also encourage maintaining a stop-loss at 20% from the entry price to manage potential downside risk effectively.

SWOT Analysis

Strength	Weakness
Laurus is the world’s leading third-party API supplier for antiretrovirals, with 68% of FY25 revenues from exports across a diversified global customer base spanning North America (20%), Europe (25%) and Rest of World (55%). Integrated CDMO platform with commercial-scale capabilities in complex technologies such as biocatalysis, flow chemistry, trickle bed hydrogenation backed by 1,505 R&D scientists and 110+ active pipeline projects across human health, animal health and crop science. Strong pipeline and rapid scale-up driving progress in both CDMO and CMO projects.	CDMO revenue remains lumpy quarter-to-quarter due to long lead-time campaign deliveries, making near-term earnings visibility limited. Heavy and sustained CAPEX cycle of Rs.1,000 crore guided each in FY26 and FY27, with an additional $600 mn greenfield over 8 years might keep asset turnover below normalised levels (currently 0.91× vs historical average of 1.1×) and ROCE below target.
Opportunities	Threats
CDMO transition from development to commercial supplies in FY27 with majority guided to come from commercial NCE supplies – unlocks recurring, sticky, high-margin revenue that structurally reduces lumpiness. Peptide and fermentation capacity coming online within CY26 positions Laurus to capture the fast-growing GLP-1, precision fermentation and large-molecule CDMO opportunity ahead of most Indian peers. KRKA JV Phase-1 (mid-2027) and new US/Canada FDF launches add durable non-ARV revenue streams, reducing concentration risk and expanding the generics earnings base beyond the current ARV-dominant mix.	Slower growth in key export markets such as the USA due to price erosion and increasing regulatory challenges that can affect market dynamics. Dependence on PEPFAR/USAID funding and Global Fund tender outcomes creates direct volume risk to the ARV business, which contributes ~40% of revenues.

Disclaimer: Investments in the securities market are subject to market risks, read all related documents carefully before investing. Securities quoted here are exemplary, not recommendatory. Please consult your financial advisor before investing. Please note that we do not guarantee any assured returns for the securities quoted here.

Research disclaimer: Investment in the securities market is subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee the performance of the intermediary or provide any assurance of returns to investors.

For more details, please read the disclaimer.